News
This section will highlight public scientific, financial and partnership disclosures. Citryll presents at conferences and aims towards publishing in peer-reviewed scientific journals.
Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Citryll Appoints Sjoerd van Gorp as Director of Operations
Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013.
Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies
Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).
Citryll Appoints CTO and CSO
Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.
Citryll Appoints Chief Medical Officer
Citryll today announced it has appointed Patrick
Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical
development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management / Biometrics, and Drug Safety.
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…
Antibodies clamp down on NET nucleosomes
In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion …
Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology
Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at …
Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases
Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed
by severe organ damage …
Citryll moves to new premises at Pivot Park in Oss, The Netherlands
Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it
has occupied new office and lab space at the Pivot Park in Oss the Netherlands.